R

Radiopharm Theranostics Ltd
NASDAQ:RADX

Watchlist Manager
Radiopharm Theranostics Ltd
NASDAQ:RADX
Watchlist
Price: 4.33 USD Market Closed
Market Cap: 10.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+10%
Revenue
Forecast
+22%
Operating Income
Forecast
+40%
Net Income
Forecast
+35%

Wall Street
Price Targets

RADX Price Targets Summary
Radiopharm Theranostics Ltd

Wall Street analysts forecast RADX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RADX is 4.43 USD with a low forecast of 4.27 USD and a high forecast of 4.67 USD.

RADX Lowest Forecast
Wall Street Target
4.27 USD
1% Downside
RADX Average Forecast
Wall Street Target
4.43 USD
2% Upside
RADX Highest Forecast
Wall Street Target
4.67 USD
8% Upside
Lowest
Price Target
4.27 USD
1% Downside
Average
Price Target
4.43 USD
2% Upside
Highest
Price Target
4.67 USD
8% Upside
Radiopharm Theranostics Ltd Competitors:
Price Targets
S
4599
StemRIM Inc
133% Upside
UTHR
United Therapeutics Corp
29% Upside
B
251120
Bio-FD&C Co Ltd
28% Upside
C
2487
Cutia Therapeutics
48% Upside
S
4599
StemRIM Inc
133% Upside
UTHR
United Therapeutics Corp
29% Upside
B
251120
Bio-FD&C Co Ltd
28% Upside
C
2487
Cutia Therapeutics
48% Upside
ABEO
Abeona Therapeutics Inc
212% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
43% Upside
OSE
OSE Immunotherapeutics SA
179% Upside
KMDA
Kamada Ltd
120% Upside

Revenue
Forecast

Revenue Estimate
Radiopharm Theranostics Ltd

The compound annual growth rate of Radiopharm Theranostics Ltd's revenue for the next 3 years is 460%.

N/A
Past Growth
460%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Radiopharm Theranostics Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
13%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Radiopharm Theranostics Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
RADX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RADX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RADX stock valuation using valuation multiples.
Wall Street Estimates
RADX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RADX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RADX's stock price target?
Price Target
4.43 USD

According to Wall Street analysts, the average 1-year price target for RADX is 4.43 USD with a low forecast of 4.27 USD and a high forecast of 4.67 USD.

What is Radiopharm Theranostics Ltd's Revenue forecast?
Projected CAGR
460%

The compound annual growth rate of Radiopharm Theranostics Ltd's revenue for the next 3 years is 460%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.